Dorton Katina — SEC Form 4 filings
SEC reporting owner CIK 1617541. 16 Form 4 filings on record with FilingPulse; latest filed 2026-07-17.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-02-20 to 2026-07-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Keenova Therapeutics plc | Director | 8 | — | — | 15 |
| Fulcrum Therapeutics, Inc. (FULC) | Director | 3 | — | — | 3 |
| TScan Therapeutics, Inc. (TCRX) | Director | 3 | — | — | 3 |
| Prelude Therapeutics Inc (PRLD) | Director | 2 | — | — | 2 |
Form 4 filings — Dorton Katina
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4 | Keenova Therapeutics plc | Grant/award (A): 4,406 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Fulcrum Therapeutics, Inc. (FULC) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Prelude Therapeutics Inc (PRLD) | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Keenova Therapeutics plc | Option exercise (M): 4,882 · Option exercise (M): 4,882 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | TScan Therapeutics, Inc. (TCRX) | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Keenova Therapeutics plc | Grant/award (A): 3,984 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Keenova Therapeutics plc | Option exercise (M): 1,808 · Tax withholding (F): 513 · Disposition to issuer (D): 1,480 (derivative) · Option exercise (M): 1,808 (derivative) @ $0 | EDGAR |
| 2025-10-20 | 4 | Prelude Therapeutics Inc (PRLD) | Grant/award (A): 76,000 (derivative) @ $0 | EDGAR |
| 2025-08-18 | 4 | Mallinckrodt plc | Grant/award (A): 4,062 (derivative) @ $0 | EDGAR |
| 2025-08-04 | 4 | Mallinckrodt plc | Grant/award (A): 16,414 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | TScan Therapeutics, Inc. (TCRX) | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Fulcrum Therapeutics, Inc. (FULC) | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4 | Mallinckrodt plc | Option exercise (M): 1,504 · Tax withholding (F): 294 · Disposition to issuer (D): 1,231 (derivative) · Option exercise (M): 1,504 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Fulcrum Therapeutics, Inc. (FULC) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | TScan Therapeutics, Inc. (TCRX) | Grant/award (A): 47,500 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Mallinckrodt plc | Grant/award (A): 8,207 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1617541 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →